Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes.
about
P1343
Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations.Serological detection of cutaneous T-cell lymphoma-associated antigensDetection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemiaFocus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human gliomaIdentification of XAGE-1 isoforms: predominant expression of XAGE-1b in testis and tumorsTreatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1Translation of a retained intron in tyrosinase-related protein (TRP) 2 mRNA generates a new cytotoxic T lymphocyte (CTL)-defined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineageIdentification of nucleolar protein No55 as a tumour-associated autoantigen in patients with prostate cancerNY-ESO-1 tumour associated antigen is a cytoplasmic protein detectable by specific monoclonal antibodies in cell lines and clinical specimensSurvey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responsesGene therapy for carcinoma of the breast: Genetic immunotherapyTumor antigens for cancer immunotherapy: therapeutic potential of xenogeneic DNA vaccinesNeoplastic "Black Ops": cancer's subversive tactics in overcoming host defensesYeast homolog of a cancer-testis antigen defines a new transcription complex.DNA vaccine for cancer immunotherapyCytokines required for induction of histocompatibility leukocyte antigen-class I-restricted and tumor-specific cytotoxic T lymphocytes by a SART1-derived peptideImmunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissuesCancer/testis antigens: an expanding family of targets for cancer immunotherapymRNA expression of leukemia-associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapiesSEREX identification of new tumour-associated antigens in cutaneous T-cell lymphomaHuman Mena protein, a serex-defined antigen overexpressed in breast cancer eliciting both humoral and CD8+ T-cell immune responseDNA vaccination of HSP105 leads to tumor rejection of colorectal cancer and melanoma in mice through activation of both CD4 T cells and CD8 T cellsPre-existing immunity to tyrosinase-related protein (TRP)-2, a new TRP-2 isoform, and the NY-ESO-1 melanoma antigen in a patient with a dramatic response to immunotherapyTrypanosoma cruzi adjuvants potentiate T cell-mediated immunity induced by a NY-ESO-1 based antitumor vaccineA novel human-derived antibody against NY-ESO-1 improves the efficacy of chemotherapyDevelopment of a humanized HLA-A2.1/DP4 transgenic mouse model and the use of this model to map HLA-DP4-restricted epitopes of HBV envelope proteinImmunosignature system for diagnosis of cancer.Seroreactivity against MAGE-A and LAGE-1 proteins in melanoma patients.Identification and characterization of 9D7, a novel human protein overexpressed in renal cell carcinoma.CML28 is a broadly immunogenic antigen, which is overexpressed in tumor cells.Murine leukemia RL male 1 and sarcoma Meth A antigens recognized by cytotoxic T lymphocytes (CTL).Expression of cancer/testis antigens in cutaneous T cell lymphomas.Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library.Identification of tumor associated antigens recognized by IgG from tumor-infiltrating B cells of lung cancer: correlation between Ab titer of the patient's sera and the clinical course.Cloning of B cell lymphoma-associated antigens using modified phage-displayed expression cDNA library and immunized patient sera.Mitofilin and titin as target antigens in melanoma-associated retinopathy.Linking the ovarian cancer transcriptome and immunomeTumor antigen analysis in neuroblastoma by serological interrogation of bioinformatic data.Clinical applications of a peptide-based vaccine for glioblastoma.Melanoma: tumor microenvironment and new treatments.
P2860
Q24533572-B8E221CD-59C6-41B1-ACDD-7E0554E6FA59Q24544114-2DECF6F1-86CC-4FE2-9BEA-F4E43132F7CCQ24604091-2D4EB45E-F502-4B6F-898B-041F430265ECQ24615166-8542FC56-E3B2-4008-8111-49DB7762D0C2Q24615209-2246DE7C-9B76-4B4F-86F5-3A52A9F13077Q24633445-77351A38-CC62-4654-8B74-0834A3E52FA4Q24646800-681BD871-3DDC-4B9B-94B4-6501321E6A91Q24648957-3C776B87-D771-4A1B-944A-4E9B85E00DEFQ24649090-74A57FB0-31FD-46AC-B82D-32E624BAF51CQ24678759-CC34C2FA-F151-4290-9D55-D1DB281C8611Q24797848-3986580D-CF8C-4254-9546-68AF4FB65689Q24804837-1DA3772B-05B6-44F8-9517-60F9A7BCDD87Q27001081-9CE2CD70-197F-441D-8134-8489644B9DAEQ27933400-81F51746-1133-416D-A7BE-2C692223F31BQ28080919-569E2363-E363-4C77-8D8A-1046C8F42A52Q28146219-1084F4C6-D7A4-487E-8869-368707B7E50FQ28188712-9DEE32E7-ACCF-4CDF-B2A4-B3DCC95AF7E3Q28215652-75572441-A36F-44FD-8A4A-3069F42E7840Q28236215-0AEC09B9-B39E-414D-A88F-25ACC7325377Q28247977-35E7C187-348B-40AD-9A80-4C392E3068E6Q28251022-73F5B09C-4D52-4ECA-B0B8-20617AD07D0CQ28277691-9C135556-F527-4620-B2CD-CB962287BD76Q28344557-64F8A711-2CA0-4189-B78F-85ADDBBBF0EEQ28483146-EF4548A2-ECC2-4A73-BE90-641D9F5CF65AQ28709361-F22DD452-474F-499E-80E0-BB97CC52E763Q28731516-9D09D13F-ED90-4631-B417-CFA5620935ADQ30585860-049A7862-2F6F-477B-B993-97F125EDD017Q30785776-E654E27D-76A2-49D7-8DBD-C9427D790D20Q30790800-A4D92068-6A8F-44CA-9067-6AE3AD67277AQ30859024-01CE049F-CF4E-43C9-8276-2679BF946301Q31023643-BEDE1269-613A-425D-8D22-643369AE2A85Q31036179-18A7E1A0-B608-4ABE-809B-C87047D77EF8Q32061664-1B1D6CAE-A426-47DC-807D-39FF1500B0B9Q33230009-C16B1328-D59F-453F-9678-07B61E7B88C9Q33240732-159C1F6F-AC2F-431D-AB76-5EA624FAC070Q33264820-426A93B0-B76F-45EE-B0BF-05272E3B6130Q33313203-2A5D5C88-4437-467D-9A81-E10705AF05C6Q33662452-2DF6A736-937E-40CB-B1BF-4D1D706CCCABQ33668575-9D3AC2EB-874E-4180-B645-FF2A189BD4C0Q33675676-DE003C7E-ABDA-4F60-B205-AE7011626790
P2860
Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes.
description
1998 nî lūn-bûn
@nan
1998 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Simultaneous humoral and cellu ...... )-A2-binding peptide epitopes.
@ast
Simultaneous humoral and cellu ...... )-A2-binding peptide epitopes.
@en
type
label
Simultaneous humoral and cellu ...... )-A2-binding peptide epitopes.
@ast
Simultaneous humoral and cellu ...... )-A2-binding peptide epitopes.
@en
prefLabel
Simultaneous humoral and cellu ...... )-A2-binding peptide epitopes.
@ast
Simultaneous humoral and cellu ...... )-A2-binding peptide epitopes.
@en
P2093
P2860
P356
P1476
Simultaneous humoral and cellu ...... )-A2-binding peptide epitopes.
@en
P2093
Drijfhout JW
Ringhoffer M
P2860
P304
P356
10.1084/JEM.187.2.265
P407
P4510
P577
1998-01-01T00:00:00Z